Martínez Arrechea Silvia, Ferro Uriguen Alexander, Beobide Telleria Idoia, González Bueno Javier, Alaba Trueba Javier, Sevilla Sánchez Daniel
Servicio de Farmacia, Hospital Ricardo Bermingham (Matia Fundazioa), San Sebastián, Guipúzcoa, España.
Servicio de Farmacia, Hospital Ricardo Bermingham (Matia Fundazioa), San Sebastián, Guipúzcoa, España.
Rev Esp Geriatr Gerontol. 2021 Jan-Feb;56(1):11-17. doi: 10.1016/j.regg.2020.09.008. Epub 2020 Dec 11.
Dementia is one of the most frequent diseases in the elderly, being its prevalence of up to 64% in institutionalized people. In this population, in addition to antidementia drugs, it is common to prescribe drugs with anticholinergic/sedative burden that, due to their adverse effects, could worsen their functionality and cognitive status. The objective is to estimate the prevalence of the use of drugs with anticholinergic/ sedative burden in institutionalized older adults with dementia and to assess the associated factors.
A cross-sectional study developed in older with dementia living in nursing homes. The prevalence of prescription of anticholinergic/sedative drugs was estimated according to the Drug Burden Index (DBI). A comparative analysis of the DBI score was performed between different types of dementia as well as among various factors and according to the anticholinergic/sedative risk, establishing as a cut-off point of DBI≥1 (high anticholinergic/sedative risk).
178 residents were included. 83.7% had some drug with anticholinergic/sedative burden according to DBI. 50% had a DBI≥1 score. Residents with vascular dementia had a mean DBI of 1.34 (SD 0.84), a significantly higher score than residents with Alzheimer's disease (0.41, 95% CI 0.04-0.78).). Likewise, a higher DBI was associated with more polypharmacy (3.36; 95% CI 2.64-4.08), more falls, hospital admissions and emergency room visits (P<.05).
Polypharmacy and prescription of anticholinergic/sedative drugs is frequent among institutionalized older adults with dementia, finding an association between DBI, falls and hospital admissions or emergency department visits. Therefore, it is necessary to propose interdisciplinary pharmacotherapeutic optimization strategies.
痴呆是老年人中最常见的疾病之一,在机构养老人群中的患病率高达64%。在这一人群中,除了抗痴呆药物外,开具具有抗胆碱能/镇静负担的药物也很常见,由于其不良反应,可能会使他们的功能和认知状态恶化。目的是估计患有痴呆的机构养老老年人中使用具有抗胆碱能/镇静负担药物的患病率,并评估相关因素。
对居住在养老院的患有痴呆的老年人开展一项横断面研究。根据药物负担指数(DBI)估计抗胆碱能/镇静药物的处方患病率。对不同类型痴呆之间以及各种因素之间的DBI评分进行比较分析,并根据抗胆碱能/镇静风险进行分析,将DBI≥1(高抗胆碱能/镇静风险)确定为截断点。
纳入178名居民。根据DBI,83.7%的人使用了具有抗胆碱能/镇静负担的某种药物。50%的人DBI≥1分。血管性痴呆患者的平均DBI为1.34(标准差0.84),显著高于阿尔茨海默病患者(0.41,95%可信区间0.04 - 0.78)。同样,较高的DBI与更多的联合用药(3.36;95%可信区间2.64 - 4.08)、更多的跌倒、住院和急诊就诊相关(P<0.05)。
在患有痴呆的机构养老老年人中,联合用药以及开具抗胆碱能/镇静药物的情况很常见,发现DBI与跌倒、住院或急诊就诊之间存在关联。因此,有必要提出跨学科的药物治疗优化策略。